BostonGene and Unilever Partner to Leverage AI Multiomics for Next-Generation Innovation

BostonGene has entered into a strategic collaboration with Unilever to apply advanced artificial intelligence and multiomics technologies to drive next-generation product innovation. The partnership will integrate BostonGene’s AI-powered analytics platform with Unilever’s research capabilities to uncover novel biological insights and accelerate the development of science-backed consumer health and wellness solutions.

AI-Powered Multiomics for Consumer Health Discovery

The collaboration aims to harness multiomics data — including genomics, proteomics, and other biological datasets — to better understand complex biological systems. By combining AI-driven data interpretation with consumer research, the companies seek to identify new pathways and targets that can inform innovative product development across health-focused portfolios.

Expanding AI Beyond Traditional Biopharma

The alliance reflects a growing trend of AI-enabled biotech platforms expanding beyond oncology and clinical research into broader consumer health applications. For Unilever, the partnership strengthens its science-led innovation strategy, while for BostonGene, it demonstrates the scalability of its AI multiomics platform across industries beyond pharmaceutical drug development.